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has been used to determine the probability of LNI. The output
of these tools has assisted surgeons in determining whether to
perform a PLND, and if so, to what extent [2–4]. The authors
hypothesize that, with additional MRI parameters not
previously used, machine-learning algorithms can better select
which patients are more likely to have LNI and will therefore
require extended PLND. In fact, the authors report that the
MSKCC nomogram and conventional MRI reporting of LNI
consistently underestimated LNI risk compared to the
machine-learning-assisted models presented in their study.
The outputs of the present models would allow a higher
number of extended PLNDs to be spared compared to reliance
on the MSKCC nomogram alone. It was appropriate to use
several existing AI models in this study, as it is never readily
apparent initially which existing predictive model may perform
best with a given dataset. In fact, all the models used – logistic
regression (LR), support vector machine (SVM) and random
forrest (RF) – while similar in performance to each other,
outperformed the MSKCC nomogram (P < 0.001). Many
adjustments were probably performed for each model to tailor
it to the dataset and optimize prediction performance.
Criticisms of the study are that: (i) cases for which PLND
was not performed were excluded, which could have created a
selection bias; (ii) the model would only be applicable when
the patient has undergone MRI; (iii) the study was conducted
at a single institution in a small sample (AI methods thrive
on big and diverse datasets).
This study by Hou et al. is a great example of a machine-
learning application that may positively impact clinical practice.
For many years, we have relied on nomograms, but with
increasing use of MRI, additional factors should also be
included, as Hou et al. have done. Machine-learning is
particularly adept at simultaneously examining numerous
variables to elicit which ones may contribute best to a particular
outcome. As BJUI has evaluated many manuscripts examining
machine-learning methods for clinical decision-making in the
past year, we have encouraged authors to use present-day gold
standard methods, such as the MSKCC nomogram, as controls
[5]. As we embrace AI methods, we must keep one eye on the
tried and true conventional ways. This ensures that we do not
take backward steps but rather take forward steps responsibly.
Similarly to recent AI studies published in the BJUI, the sample
size in this study was relatively small. External validation in a
multicentre study on larger datasets is highly recommended.
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How long is long enough for pharmacological
thromboprophylaxis in urology?
Each year, millions of patients who undergo urological surgery
incur the risk of deep vein thrombosis and pulmonary
embolism, together referred to as venous thromboembolism
(VTE), and major bleeding. Because pharmacological
prophylaxis decreases the risk of VTE, but increases the risk of
bleeding, and because knowledge of the magnitude of these risks
remains uncertain, both clinical practice and guideline
recommendations vary widely [1]. One of the uncertainties is the
recommended duration of pharmacological thromboprophylaxis.
In this issue of the BJUI, Naik et al. [2] provide an
up-to-date review that summarise the articles that
examined extended thromboprophylaxis in patients with
cancer who underwent radical prostatectomy (RP),
radical cystectomy (RC) or nephrectomy. The outcomes
on which they focussed include risks of VTE,
bleeding, renal failure and mortality – all potentially
inﬂuenced by whether or not patients receive extended
prophylaxis.
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After screening >3500 articles, the authors included 18 studies,
none of them randomised controlled trials (RCTs) [2]. They
found that VTE risk is highest in open and robot-assisted RC,
and that, based on observational studies, extended
thromboprophylaxis signiﬁcantly reduces the risk of VTE relative
to shorter duration prophylaxis. Evidence suggested that robot-
assisted RP, as well as both open and robot-assisted partial and
radical nephrectomies, incur lower VTE risk than RCs or open
RP. They did not ﬁnd studies comparing extended prophylaxis to
standard prophylaxis for RPs or nephrectomies [2].
Overall, these ﬁndings are consistent with systematic reviews
that estimated the procedure- and patient risk factor-speciﬁc
risks for 20 urological cancer procedures [3]. As these reviews
suggested substantial procedure-speciﬁc differences in the
VTE risk estimates, the European Association of Urology
(EAU) Guidelines provided separate recommendations for
each procedure [4]. For urological (as well as gastrointestinal
and gynaecological) patients, the National Institute for Health
and Care Excellence (NICE) Guidelines suggest to ‘consider
extending pharmacological VTE prophylaxis to 28 days
postoperatively for people who have had major cancer
surgery in the abdomen’ [5]. Because of variation in both
bleeding and thrombosis risks across procedures, this advice
is appropriate for some procedures and misguided for others.
For instance, the procedure-speciﬁc EAU Guidelines
recommend extended VTE prophylaxis for open RC but not
for robot-assisted RP without lymphadenectomy [4].
The review by Naik et al. [2] identiﬁed the lack of urology-
speciﬁc studies comparing the in-hospital-only prophylaxis to
extended prophylaxis. The few included studies were
observational with considerable limitations (e.g., limited
adjustment for possible confounders).
A recent update of a Cochrane review compared the impact
of extended thromboprophylaxis with low-molecular-weight
heparin (LMWH) for at least 14 days to in-hospital-only
prophylaxis in abdominal or pelvic surgery procedures [6].
The authors identiﬁed seven RCTs (1728 participants)
evaluating extended thromboprophylaxis with LMWH and
generated pooled estimates for the incidence of any VTE
(symptomatic or asymptomatic) after major abdominal or
pelvic surgery of 13.2% in the control group compared with
5.3% in the patients receiving extended out-of-hospital
LMWH (odds ratio [OR] 0.38, 95% CI 0.26–0.54).
Most events were asymptomatic, although the incidence of
symptomatic VTE was also reduced from 1.0% in the in-hospital-
only group to 0.1% in patients receiving extended
thromboprophylaxis (OR 0.30, 95% CI 0.08–1.11). The authors
reported no persuasive difference in the incidence of bleeding
complications within 3 months of surgery (deﬁned as major or
minor bleeding according to the deﬁnition provided in the
individual studies) between the in-hospital-only group (2.8%)
and extended LMWH (3.4%) group (OR 1.10, 95% CI 0.67–1.81).
These ﬁndings are consistent with our own modelling study
that demonstrated an approximately constant hazard of VTE
up to 4 weeks after surgery [7]. That study also found that
bleeding risk, by contrast, is concentrated in the ﬁrst 4 days
after surgery [7] (Fig. 1). Using these ﬁndings, the EAU
Guidelines suggest for patients in whom pharmacological
prophylaxis is appropriate, extended pharmacological
prophylaxis for 4 weeks [4]. Consistent with these
recommendations, Naik et al. [2] found that 15 studies of 18
included in their review recommended extended prophylaxis.
Overall, as shown also by this review [2], the evidence base for
urological thromboprophylaxis is limited. Although current
evidence supports extended prophylaxis, deﬁnitively establishing
the optimal duration of thromboprophylaxis will require large-
scale RCTs. Other unanswered key questions include: baseline
risks of various procedures, timing of prophylaxis, patient risk
stratiﬁcation, as well as effectiveness of direct oral
anticoagulants. In the meanwhile, suggesting extended duration
to patients whose risk of VTE is sufﬁciently high constitutes a
reasonable evidence-based approach to VTE prophylaxis.
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Fig. 1 Proportion of cumulative risk (%) of venous thromboembolism (VTE)
and major bleeding by week since surgery during the ﬁrst 4 postoperative
weeks. Reproduced from: Tikkinen et al. [7]. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (https://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
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Society of Hematology (ASH) Guideline Panel on Prevention
of Venous Thromboembolism (VTE) in Surgical Hospitalized
Patients.
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